This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutIndicationsBroad CoverageEfficacyEfficacyLimited Treatment OptionsSafetySafety

Safety Profile Summary 

DosingAdult DosingPaediatric Dosing

Prescribing Information

Safety
Zavicefta (ceftazidime-avibactam) has a safety and tolerability profile consistent with both cephalosporins and carbapenems1-4
  • Overall rates of any AE were low in the ZAVICEFTA (ceftazidime–avibactam) and comparator arms1-4
  • Rates of all other categories of AEs were low and balanced across treatment arms1-4
  • Most common (≥ 5%) AEs for ZAVICEFTA were positive direct Coombs test, nausea and diarrhoea5*
  • Nausea and diarrhoea were usually mild or moderate in intensity1-5
  • No requirement for routine monitoring and a low potential for drug–drug interactions5
  • In four Phase III clinical trials, the adverse-event profile of ZAVICEFTA was similar to that seen with either best-available therapy, doripenem or meropenem.1-4

*Based on data from seven Phase II and Phase III clinical trials in 2024 adult patients treated with ZAVICEFTA.5

Prescribing information

Zavicefta® (avibactam sodium, ceftazidime pentahydrate)

Zavicefta® (avibactam sodium, ceftazidime pentahydrate) 2g/0.5g powder for concentrate for
solution for infusion
)

Meronem® (meropenem trihydrate) 

Meronem® (Meropenem Trihydrate) Meronem I.V. 1g

Abbreviations:AE, adverse event; References:Mazuski JE, et al. Clin Infect Dis 2016;62:1380–9.Carmeli Y, et al. Lancet Infect Dis 2016;16:661–73.Torres A, et al. Lancet Infect Dis 2018;18:285–95.Wagenlehner FM, et al. Clin Infect Dis 2016;63:754–62.

ZAVICEFTA. Summary of Product Characteristics.

Safety

Legal Category: S1A

Further information available upon request

PP-ZVA-IRL-0288. December 2024

Adverse events should be reported.

If you wish to make a medical information inquiry or report an adverse event please contact Pfizer on 1800 633 363 
or email Pfizer at [email protected] or visit www.PfizerMedicalInformation.ie

Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.  Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0891. February 2025
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0891. February 2025

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0891. February 2025